ResearchMoz

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies

GBI Research
Published Date » 2013-09-23
No. Of Pages » N/A
   
 GBI Research, the leading business intelligence provider, has released its latest research: Solid Tumors in Asia-Pacific Market to 2019 - New and Anticipated Approvals of Targeted Therapies to Trigger a Shift in Treatment Paradigm, which provides in-depth analysis of four key therapeutic indications within the Asia-Pacific (APAC) solid tumors market – bladder cancer, ovarian cancer, pancreatic cancer and prostate cancer – covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these four solid tumor types.  
   
 The value...
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Solid Tumors Market in Asia Pacific to 2019 - Introduction
2.1 Introduction

3 Solid Tumors Market in Asia Pacific to 2019 - Therapeutic Landscape
3.1 Bladder Cancer
3.1.1 Symptoms
3.1.2 Etiology
3.1.3 Pathophysiology
3.1.4 Diagnosis
3.1.5 Classification
3.1.6 Epidemiology
3.1.7 Prognosis and Disease Staging
3.1.8 Treatment Options
3.2 Ovarian Cancer
3.2.1 Symptoms
3.2.2 Etiology
3.2.3 Pathophysiology
3.2.4 Diagnosis
3.2.5 Classification
3.2.6 Epidemiology
3.2.7 Prognosis and Disease Staging
3.2.8 Treatment Options
3.3 Pancreatic Cancer
3.3.1 Symptoms
3.3.2 Etiology
3.3.3 Pathophysiology
3.3.4 Diagnosis
3.3.5 Classification
3.3.6 Epidemiology
3.3.7 Prognosis and Disease Staging
3.3.8 Treatment Algorithm
3.4 Prostate Cancer
3.4.1 Symptoms
3.4.2 Etiology
3.4.3 Pathophysiology
3.4.4 Co-Morbidities and Complications
3.4.5 Diagnosis
3.4.6 Classification
3.4.7 Epidemiology
3.4.8 Prognosis and Disease Staging
3.4.9 Treatment Options

4 Solid Tumors Market in Asia Pacific to 2019 - Marketed Products
4.1 Bladder Cancer
4.2 Ovarian Cancer
4.3 Pancreatic Cancer
4.4 Prostate Cancer
4.5 Key Marketed Products
4.5.1 Carboplatin
4.5.2 Cisplatin
4.5.3 Gemcitabine
4.5.4 Paclitaxel
4.5.5 Doxorubicin
4.5.6 Avastin (bevacizumab)
4.5.7 Tarceva (erlotinib)
4.5.8 Sutent (sunitinib)
4.5.9 Afinitor (everolimus)
4.5.10 Taxotere (docetaxel)
4.5.11 Zytiga (abiraterone acetate)
4.5.12 Jevtana (cabazitaxel)

5 Solid Tumors Market in Asia Pacific to 2019 - Pipeline Analysis
5.1 Bladder Cancer Pipeline
5.1.1 Overall Pipeline
5.1.2 Pipeline Analysis by Molecule Type
5.1.3 Pipeline Analysis by Mechanism of Action
5.2 Ovarian Cancer Pipeline
5.2.1 Overall Pipeline
5.2.2 Pipeline Analysis by Molecule Type
5.2.3 Pipeline Analysis by Mechanism of Action
5.3 Pancreatic Cancer Pipeline
5.3.1 Overall Pipeline
5.3.2 Pipeline Analysis by Molecule Type
5.3.3 Pipeline Analysis by Mechanism of Action
5.4 Prostate Cancer Pipeline
5.4.1 Overall Pipeline
5.4.2 Pipeline Analysis by Molecule Type
5.4.3 Pipeline Analysis by Mechanism of Action
5.5 Promising Drug Candidates in the Pipeline
5.5.1 Abraxane (albumin-bound paclitaxel)
5.5.2 AMG 386 (trebananib)
5.5.3 Votrient (pazopanib)
5.5.4 Xtandi (enzalutamide)

6 Solid Tumors Market in Asia Pacific to 2019- Market Forecast
6.1 Asia-Pacific Market
6.1.1 Treatment Usage Patterns
6.1.2 Annual Cost of Treatment
6.1.3 Market Size
6.2 India
6.2.1 Treatment Usage Patterns
6.2.2 Annual Cost of Treatment
6.2.3 Market Size
6.3 Australia
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Treatment
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Treatment
6.4.3 Market Size
6.5 Japan
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Treatment
6.5.3 Market Size
6.6 Drivers and Barriers for the Solid Tumors Market in APAC
6.6.1 Drivers
6.6.2 Barriers

7 Solid Tumors Market in Asia Pacific to 2019 - Deals and Strategic Consolidations
7.1 Deals Analysis
7.2 Major Co-Development Deals
7.2.1 ScinoPharm Taiwan and Coland Enter into Agreement to Develop Generic Oncological Drugs
7.2.2 Bind Biosciences Enters into Agreement with Amgen to Develop Cancer Drugs
7.2.3 Merck Enters into Co-Development Agreement with Endocyte for Cancer Drug
7.2.4 Merck Serono Enters into Co-Development Agreement with Threshold Pharma for TH-302,
Pancreatic Cancer Drug
7.2.5 Seattle Genetics Exercises Option for Co-Development Agreement with Agensys (affiliate of
Astellas) for ASG-15ME
7.3 Major Licensing Deals
7.3.1 Spectrum Pharma Amends Licensing Agreement with Allergan for Apaziquone
7.3.2 Chugai Pharma Enters Into Licensing Agreement with Debiopharm Group for FF284
7.3.3 Baxter International Enters into Licensing Agreement with Onconova Therapeutics for
Rigosertib
7.3.4 Dyax Enters Into Licensing Agreement with Kadmon for Oncology Drug
7.3.5 Medigene Extends Licensing Agreement with Syncore for EndoTAG-1

8 Solid Tumors Market in Asia Pacific to 2019 - Appendix
8.1 Pipeline Drugs by Phase
8.1.1 Phase III
8.1.2 Pre-registration/NDA-filed
8.2 Market Forecasts to 2018
8.2.1 APAC
8.2.2 Australia
8.2.3 China
8.2.4 India
8.2.5 Japan
8.3 Market Definitions
8.4 Abbreviations
8.5 Sources
8.6 Research Methodology
8.6.1 Coverage
8.6.2 Secondary Research
8.6.3 Primary Research
8.6.4 Therapeutic Landscape
8.6.5 Geographical Landscape
8.6.6 Pipeline Analysis
8.7 Expert Panel Validation
8.8 Contact Us
8.9 Disclaimer

List of Tables


Table 1: Solid Tumors Market, Bladder Cancer, AJCC TNM Staging System, 2010
Table 2: Solid Tumors Market, Bladder Cancer, Treatment by Staging, 2013
Table 3: Solid Tumors Market, Ovarian Cancer, AJCC’s TNM and FIGO Staging Systems, 2013
Table 4: Solid Tumors Market, Pancreatic Cancer, AJCC TNM Staging System, 2013
Table 5: Solid Tumors Market, Prostate Cancer, AJCC Staging System, 2013
Table 6: Solid Tumors Market, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 7: Solid Tumors Market, Global, Pharmaceutical Pipeline (Pre-registration/NDA-filed), 2013
Table 8: Solid Tumors Market, Asia-Pacific, Ovarian Cancer, Market Forecast, 2012–2019
Table 9: Solid Tumors Market, Asia-Pacific, Bladder Cancer, Market Forecast, 2012–2019
Table 10: Solid Tumors Market, Asia-Pacific, Pancreatic Cancer, Market Forecast, 2012–2019
Table 11: Solid Tumors Market, Asia-Pacific, Prostate Cancer, Market Forecast, 2012–2019
Table 12: Solid Tumors Market, Australia, Ovarian Cancer, Market Forecast, 2012–2019
Table 13: Solid Tumors Market, Australia, Bladder Cancer, Market Forecast, 2012–2019
Table 14: Solid Tumors Market, Australia, Pancreatic Cancer, Market Forecast, 2012–2019
Table 15: Solid Tumors Market, Australia, Prostate Cancer, Market Forecast, 2012–2019
Table 16: Solid Tumors Market, China, Ovarian Cancer, Market Forecast, 2012–2019
Table 17: Solid Tumors Market, China, Bladder Cancer, Market Forecast, 2012–2019
Table 18: Solid Tumors Market, China, Pancreatic Cancer, Market Forecast, 2012–2019
Table 19: Solid Tumors Market, China, Prostate Cancer, Market Forecast, 2012–2019
Table 20: Solid Tumors Market, India, Ovarian Cancer, Market Forecast, 2012–2019
Table 21: Solid Tumors Market, India, Bladder Cancer, Market Forecast, 2012–2019
Table 22: Solid Tumors Market, India, Pancreatic Cancer, Market Forecast, 2012–2019
Table 23: Solid Tumors Market, India, Prostate Cancer, Market Forecast, 2012–2019
Table 24: Solid Tumors Market, Japan, Ovarian Cancer, Market Forecast, 2012–2019
Table 25: Solid Tumors Market, Japan, Bladder Cancer, Market Forecast, 2012–2019
Table 26: Solid Tumors Market, Japan, Pancreatic Cancer, Market Forecast, 2012–2019
Table 27: Solid Tumors Market, Japan, Prostate Cancer, Market Forecast, 2012–2019

List of Figures


Figure 1: Solid Tumors Market, Asia-Pacific, Bladder Cancer, Epidemiology, 2012–2019
Figure 2: Solid Tumors Market, Bladder Cancer, Treatment Algorithm, Superficial and Stage I, 2013
Figure 3: Solid Tumors Market, Bladder Cancer, Treatment Algorithm, Stage II and III, 2013
Figure 4: Solid Tumors Market, Asia-Pacific, Ovarian Cancer, Epidemiology, 2012–2019
Figure 5: Solid Tumors Market, Ovarian Cancer, Treatment Algorithm, Stage I and II, 2013
Figure 6: Solid Tumors Market, Ovarian Cancer, Treatment Algorithm, Stage III and IV, 2013
Figure 7: Solid Tumors Market, Asia-Pacific, Pancreatic Cancer, Epidemiology, 2012–2019
Figure 8: Solid Tumors Market, Pancreatic Cancer, Treatment Algorithm, 2013
Figure 9: Solid Tumors Market, Asia-Pacific, Prostate Cancer, Epidemiology, 2012–2019
Figure 10: Solid Tumors Market, Prostate Cancer, Treatment Algorithm, 2013
Figure 11: Solid Tumors Market, Global, Avastin, Annual Sales ($m), 2006–2013e
Figure 12: Solid Tumors Market, Global, Tarceva, Annual Sales ($m), 2006–2013e
Figure 13: Solid Tumors Market, Global, Sutent, Annual Sales ($m), 2006–2013e
Figure 14: Solid Tumors Market, Global, Afinitor, Annual Sales ($m), 2009–2013e
Figure 15: Solid Tumors Market, Global, Zytiga, Annual Sales ($m), 2011–2013e
Figure 16: Solid Tumors Market, Global, Jevtana, Annual Sales ($m), 2010–2013e
Figure 17: Solid Tumors Market, Global, Bladder Cancer, Pipeline, 2013
Figure 18: Solid Tumors Market, Global, Bladder Cancer, Pipeline by Molecule Type, 2013
Figure 19: Solid Tumors Market, Global, Bladder Cancer, Pipeline by Mechanism of Action, 2013
Figure 20: Solid Tumors Market, Global, Ovarian Cancer, Pipeline, 2013
Figure 21: Solid Tumors Market, Global, Ovarian Cancer, Pipeline by Molecule Type, 2013
Figure 22: Solid Tumors Market, Global, Ovarian Cancer, Pipeline by Mechanism of Action, 2013
Figure 23: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline, 2013
Figure 24: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline by Molecule Type, 2013
Figure 25: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline by Mechanism of Action, 2013
Figure 26: Solid Tumors Market, Global, Prostate Cancer, Pipeline, 2013
Figure 27: Solid Tumors Market, Global, Prostate Cancer, Pipeline by Molecule Type, 2013
Figure 28: Solid Tumors Market, Global, Prostate Cancer, Pipeline by Mechanism of Action, 2013
Figure 29: Solid Tumors Market, Asia-Pacific, Market Size ($m), 2012–2019
Figure 30: Solid Tumors Market, India, Market Size ($m), 2012–2019
Figure 31: Solid Tumors Market, Australia, Market Size ($m), 2012–2019
Figure 32: Solid Tumors Market, China, Market Size ($m), 2012–2019
Figure 33: Solid Tumors Market, Japan, Market Size ($m), 2012–2019
Figure 34: Solid Tumors Market, Global, Deals, 2006–2013
Figure 35: Solid Tumors Market, Global, Co-development Deals, 2006–2013
Figure 36: Solid Tumors Market, Global, Licensing Deals, 2006-2013
Figure 37: GBI Research Market Forecasting Model

Upcoming Reports:

Greece: lentils market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the lentils market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the lentils market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...
2,5-Dichloroaniline Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
2,5 dichloroaniline, also known as m-Dichloroaniline and 3,5-Dichlorobenzenamine is a brown to white solid which has melting point 50oC to 53oC and boiling point 261oC. It is soluble in most organic solvents but insoluble in water. It is an amine which is used as an intermediate in the production of many products that include azo dyes, agricultural chemicals, pigments and pharmaceuticals among others. Aromatic amines are weaker bases than aliphatic. The most important aromatic amine is aniline, an amine (primary) which gets replaced with an amino group in the place of hydrogen...
Poland: wood boards market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the wood boards market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the wood boards market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Nuclear Development Plans in China Gets Fresh Impetus
Mar 5, 2015  
The nuclear development plans of China got a renewed momentum on Wednesday as State Council gave a nod to build new reactors at the nuclear power plant located near Hongyan River. The unit 5 and 6 of the nuclear plant near Hongyan River, located in the northeastern province of Liaoning got approval for construction from the State Council. The council also mentioned that the construction should...
Indian Telecoms Bid at Spectrum War
Mar 5, 2015  
The Indian government on Wednesday managed to mop up nearly INR 60,000 crore with the spectrum auctions off to a wonderful start. Top bidders included Idea Cellular, Bharti Airtel, and Vodafone India who fought tooth and nail to gain secure airwaves in those areas where their licenses were nearing expiration. Reliance Jio Infocomm made a strenuous attempt to acquire as many data airwaves as...
South Korean Pharmaceutical Companies Extend Business with Saudi Arabia
Mar 5, 2015  
Four South Korean pharmaceutical companies will export their products to Saudi Arabia, including anticancer drugs and antibiotics, for the coming five years, South Korea’s Health Ministry informed this Wednesday, as a result of South Korean President Park Geun-hye's business trip to the Saudi Arabia this week. Ascertaining to the export agreement, representatives of these four Korean...
U.K. Government Slow to Stop Pharma R&D Slump
Mar 4, 2015  
When it comes to turnaround strategies, the focal point of the U.K. government is currently the life sciences industry. Recent data however shows that healthcare companies are spending less and less on research and development processes on drugs in the country. The Office of National Statistics released the data earlier this week. It shows the United Kingdom’s drug production...
Sun Pharma Buys Out GSK Australian Opiates Business
Mar 4, 2015  
Global pharmaceutical giant GSK announced on Tuesday that they had come to an agreement with Sun Pharmaceuticals Industries for the latter to buy out the opiates business in Australia owned by GSK. A joint statement was made by the two pharma top companies. The statement said that the companies’ respective wholly owned subsidiaries had already come to an agreement that was...